Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 14/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 9/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15848086 | 0.91 | MAPT (0.61) | TP53MAPTPOLBLMNAKDM4E | |
| SCHEMBL15847752 | 0.86 | MAPT (0.62) | TP53MAPTPOLBLMNA | |
| SCHEMBL15847804 | 0.84 | TP53 (0.48) | TP53MAPTPOLBLMNAKDM4E | |
| SCHEMBL17465669 | 0.82 | TP53 (0.49) | TP53MAPTPOLBLMNA | |
| SCHEMBL25404240 | 0.81 | PARG (0.50) | LMNAUSP2ALDH1A1 | |
| SCHEMBL25404892 | 0.81 | PARG (0.50) | USP2 | |
| SCHEMBL15848014 | 0.81 | MAPT (0.58) | TP53MAPTPOLBLMNAKDM4E | |
| SCHEMBL26688687 | 0.80 | ALDH1A1 (0.53) | USP2ALDH1A1 | |
| SCHEMBL18948563 | 0.78 | TP53 (0.51) | TP53MAPTPOLBLMNAKDM4E | |
| SCHEMBL15076500 | 0.77 | MAPT (0.52) | TP53MAPTPOLBLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, EIF2AK2, NR1H4 | TP53 3039/4885MAPT 4494/4885POLB 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.